Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levamisole plus budesonide/formoterol added to standard treatment for hospitalized COVID-19
IRCT20200324046852N1Phase 3Completed
- Sponsor
- Fasa University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of levamisole, budesonide, formoterol, hydroxychloroquine, lopinavir and 1 more in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Fasa University of Medical Sciences. Primary endpoints: Elimination of disease signs, Elimination of lymphopenia and 2 more. Started Apr 2020; status: completed.
02
Drugs
levamisolebudesonideformoterolhydroxychloroquinelopinavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200324046852N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200324046852N1.